Vizilo T L, Arefieva E G
Kemerovo State Medical University, Kemerovo, Russia.
Barbarash Kuzbass Clinical Cardiological Dispensary, Kemerovo, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(3):51-55. doi: 10.17116/jnevro202312303151.
To study the efficacy and safety of sequential therapy with Mexidol (500 mg 1 time/day for 14 days intravenously) and Mexidol FORTE 250 (Mexidol FORTE 250 for 250 mg 3 times/day, 60 days) in patients with chronic cerebral ischemia (CCI) on an outpatient basis.
The open comparative study included 56 patients aged 46-74 years, age - 60.5+7.9 years. In all patients, the diagnosis of CCI was confirmed by clinical and neuroimaging methods. Patients of group 1 (=28) received basic therapy and Mexidol, group 2 (=28) received only basic therapy.
Against the background of therapy in patients of group 1, there was a statistically significant improvement in the state of cognitive functions, a decrease in the severity of symptoms of depression and anxiety, manifestations of asthenia. The treatment was characterized by good tolerability, absence of adverse events and cases of drug interactions.
Sequential therapy with Mexidol and Mexidol FORTE 250 drugs provides relief of the main clinical manifestations of CCI, is characterized by good tolerability and safety.
研究美西多（静脉注射，500毫克，每日1次，共14天）和美西多福250（美西多福250，250毫克，每日3次，共60天）序贯疗法对门诊慢性脑缺血（CCI）患者的疗效和安全性。
这项开放性对照研究纳入了56例年龄在46 - 74岁之间的患者，平均年龄为60.5±7.9岁。所有患者均通过临床和神经影像学方法确诊为CCI。第1组（n = 28）患者接受基础治疗和美西多，第2组（n = 28）患者仅接受基础治疗。
在第1组患者的治疗过程中，认知功能状态有统计学意义的改善，抑郁和焦虑症状的严重程度降低，虚弱症状减轻。该治疗耐受性良好，未出现不良事件和药物相互作用的情况。
美西多和美西多福250药物序贯疗法可缓解CCI的主要临床表现，耐受性良好且安全。
